The Medicine Shoppe Pharmacy

medicineshoppe.ca

Programs / Services Specialized Programs and Services for Unique Health Needs At The Medicine Shoppe® pharmacy, we’re committed to providing a higher level of customer care. We continuously strive to find ways to better serve the people of our communities, and we’re devoted to providing the kind of personal attention you just can’t find anywhere else.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

KAIROS PHARMA RECEIVED FDA APPROVAL OF THE IND APPLICATION FOR AN INVESTIGATIONAL NEW DRUG

Kairos Pharma, Ltd. | March 15, 2022

news image

Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles. John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the secon...

Read More

PHARMACY MARKET

CSTONE AND LEGOCHEM BIOSCIENCES ENTER GLOBAL LICENSING AGREEMENT FOR NEW ANTIBODY DRUG CONJUGATE

CStone | October 29, 2020

news image

CStone Pharmaceuticals declared today a permitting concurrence with Lego Chem Bio sciences, Inc, for the turn of events and commercialization of LCB71, a likely first-in-class/top tier immunizer drug form ("ADC"). Under the understanding, CStone gets the selective worldwide option to lead advancement and commercialization of LCB71 outside the Republic of Korea. LCB will get a forthright installment of US$10 million, and up to US$353.5 million in combined achievement inst...

Read More

PRACTICE MANAGEMENT

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Farxiga | January 07, 2021

news image

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More

PHARMA TECH

FAREVA AND APIJECT SIGN A LICENSING AGREEMENT TO CREATE A FRANCE-BASED 500M UNIT ANNUAL CAPACITY FOR SINGLE-DOSE PREFILLED VACCINE INJECTIONS

ApiJect Systems Corp. | December 10, 2021

news image

Fareva and ApiJect Systems, Corp. announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry ...

Read More
news image

PHARMACY MARKET

KAIROS PHARMA RECEIVED FDA APPROVAL OF THE IND APPLICATION FOR AN INVESTIGATIONAL NEW DRUG

Kairos Pharma, Ltd. | March 15, 2022

Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles. John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the secon...

Read More
news image

PHARMACY MARKET

CSTONE AND LEGOCHEM BIOSCIENCES ENTER GLOBAL LICENSING AGREEMENT FOR NEW ANTIBODY DRUG CONJUGATE

CStone | October 29, 2020

CStone Pharmaceuticals declared today a permitting concurrence with Lego Chem Bio sciences, Inc, for the turn of events and commercialization of LCB71, a likely first-in-class/top tier immunizer drug form ("ADC"). Under the understanding, CStone gets the selective worldwide option to lead advancement and commercialization of LCB71 outside the Republic of Korea. LCB will get a forthright installment of US$10 million, and up to US$353.5 million in combined achievement inst...

Read More
news image

PRACTICE MANAGEMENT

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Farxiga | January 07, 2021

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More
news image

PHARMA TECH

FAREVA AND APIJECT SIGN A LICENSING AGREEMENT TO CREATE A FRANCE-BASED 500M UNIT ANNUAL CAPACITY FOR SINGLE-DOSE PREFILLED VACCINE INJECTIONS

ApiJect Systems Corp. | December 10, 2021

Fareva and ApiJect Systems, Corp. announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry ...

Read More